QT Assessment in Early Clinical Development Can the Predictive Value be Enhanced to be Similar to That of a TQT study?

Posted:
15
January 2012

Following the JCP Nov 2011 publication proposing food as a viable means for demonstrating assay sensitivity for ECG assessment in clinical trials, this is now proposed alongside other potential methods at the upcoming CSRC ThinkTank meeting on QT Assessment in Early Clinical Development being held 2 Feb at the FDA Headquarters in Silver Spring.The purpose of these meetings is the formation of collaborative CSRC research groups with members from regulators, sponsors and academia with the goal to perform, promote and compile research in areas addressing identified key knowledge gaps.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more